---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-036888"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:25:36.123739+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MoonLake Phase 2 ARGO trial meets primary endpoint; sonelokimab ACR50 46-47% vs placebo

## Summary
- ACR50 achieved by 46% (60mg) and 47% (120mg) with induction at week 12 (p<0.01 vs placebo; ITT-NRI).
- Key secondary endpoint PASI90 reached by 77% (60mg) and PASI100 by 58% (60mg) at week 12.
- Discontinuation rate <4%; no new safety signals; oral candidiasis <2%, no IBD/MACE/SI/B.
- Sonelokimab numerically outperformed adalimumab on primary and key secondary endpoints.
- Company plans Phase 3 in PsA; end-of-Phase 2 regulatory meeting timing to be announced.

## SEC filing metadata
- accession: 0001628280-23-036888
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000162828023036888/0001628280-23-036888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000162828023036888/mltx-20231105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-036888
- JSON: https://secwatch.observer/filing/0001628280-23-036888.json
- Plain text: https://secwatch.observer/filing/0001628280-23-036888.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.